Annual Net Income
-$25.09 M
+$33.48 M+57.16%
31 December 2023
Summary:
Rigel Pharmaceuticals annual net profit is currently -$25.09 million, with the most recent change of +$33.48 million (+57.16%) on 31 December 2023. During the last 3 years, it has risen by +$4.65 million (+15.64%). RIGL annual net income is now -166.22% below its all-time high of $37.89 million, reached on 31 December 2010.RIGL Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Net Income
$12.42 M
+$13.45 M+1305.92%
30 September 2024
Summary:
Rigel Pharmaceuticals quarterly net profit is currently $12.42 million, with the most recent change of +$13.45 million (+1305.92%) on 30 September 2024. Over the past year, it has increased by +$18.11 million (+318.22%). RIGL quarterly net income is now -75.37% below its all-time high of $50.43 million, reached on 30 September 2010.RIGL Quarterly Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Net Income
$3.88 M
+$18.11 M+127.27%
30 September 2024
Summary:
Rigel Pharmaceuticals TTM net profit is currently $3.88 million, with the most recent change of +$18.11 million (+127.27%) on 30 September 2024. Over the past year, it has increased by +$28.31 million (+115.89%). RIGL TTM net income is now -90.16% below its all-time high of $39.44 million, reached on 31 March 2011.RIGL TTM Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RIGL Net Income Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +57.2% | +318.2% | +115.9% |
| 3 y3 years | +15.6% | +159.3% | +126.8% |
| 5 y5 years | +64.4% | +208.1% | +108.3% |
RIGL Net Income High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -40.1% | +57.2% | at high | +145.3% | at high | +104.6% |
| 5 y | 5 years | -40.1% | +64.4% | -68.5% | +145.3% | at high | +104.6% |
| alltime | all time | -166.2% | +81.0% | -75.4% | +132.9% | -90.2% | +102.9% |
Rigel Pharmaceuticals Net Income History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $12.42 M(-1305.9%) | $3.88 M(-127.3%) |
| June 2024 | - | -$1.03 M(-87.5%) | -$14.23 M(-28.1%) |
| Mar 2024 | - | -$8.25 M(-1219.0%) | -$19.80 M(-21.1%) |
| Dec 2023 | -$25.09 M(-57.2%) | $737.00 K(-112.9%) | -$25.09 M(+2.7%) |
| Sept 2023 | - | -$5.69 M(-13.8%) | -$24.43 M(-35.3%) |
| June 2023 | - | -$6.60 M(-51.2%) | -$37.77 M(-15.4%) |
| Mar 2023 | - | -$13.54 M(-1066.2%) | -$44.66 M(-23.7%) |
| Dec 2022 | -$58.57 M(+227.0%) | $1.40 M(-107.4%) | -$58.57 M(-29.1%) |
| Sept 2022 | - | -$19.04 M(+41.1%) | -$82.61 M(-2.3%) |
| June 2022 | - | -$13.49 M(-50.8%) | -$84.53 M(-0.4%) |
| Mar 2022 | - | -$27.45 M(+21.2%) | -$84.86 M(+373.7%) |
| Dec 2021 | -$17.91 M(-39.8%) | -$22.64 M(+8.1%) | -$17.91 M(+23.5%) |
| Sept 2021 | - | -$20.95 M(+51.6%) | -$14.51 M(+87.7%) |
| June 2021 | - | -$13.82 M(-135.0%) | -$7.73 M(-32.7%) |
| Mar 2021 | - | $39.50 M(-305.3%) | -$11.49 M(-61.4%) |
| Dec 2020 | -$29.74 M(-55.5%) | -$19.24 M(+35.7%) | -$29.74 M(+7.4%) |
| Sept 2020 | - | -$14.17 M(-19.4%) | -$27.71 M(+10.7%) |
| June 2020 | - | -$17.58 M(-182.7%) | -$25.02 M(-10.8%) |
| Mar 2020 | - | $21.24 M(-223.5%) | -$28.05 M(-58.1%) |
| Dec 2019 | -$66.89 M(-5.1%) | -$17.20 M(+49.7%) | -$66.89 M(+44.0%) |
| Sept 2019 | - | -$11.49 M(-44.2%) | -$46.47 M(-20.9%) |
| June 2019 | - | -$20.61 M(+17.1%) | -$58.74 M(-7.8%) |
| Mar 2019 | - | -$17.60 M(-645.2%) | -$63.69 M(-9.6%) |
| Dec 2018 | -$70.48 M(-9.6%) | $3.23 M(-113.6%) | -$70.48 M(-29.2%) |
| Sept 2018 | - | -$23.77 M(-7.0%) | -$99.58 M(+6.5%) |
| June 2018 | - | -$25.56 M(+4.8%) | -$93.47 M(+7.4%) |
| Mar 2018 | - | -$24.39 M(-5.7%) | -$87.06 M(+11.6%) |
| Dec 2017 | -$77.99 M(+12.7%) | -$25.87 M(+46.5%) | -$77.99 M(+15.2%) |
| Sept 2017 | - | -$17.66 M(-7.8%) | -$67.71 M(-6.8%) |
| June 2017 | - | -$19.15 M(+25.0%) | -$72.68 M(+8.4%) |
| Mar 2017 | - | -$15.31 M(-1.8%) | -$67.07 M(-3.1%) |
| Dec 2016 | -$69.22 M(+34.5%) | -$15.59 M(-31.1%) | -$69.22 M(+4.4%) |
| Sept 2016 | - | -$22.63 M(+67.2%) | -$66.31 M(+31.7%) |
| June 2016 | - | -$13.53 M(-22.5%) | -$50.36 M(-0.7%) |
| Mar 2016 | - | -$17.46 M(+37.7%) | -$50.73 M(-1.4%) |
| Dec 2015 | -$51.46 M(-43.4%) | -$12.69 M(+90.2%) | -$51.46 M(-15.7%) |
| Sept 2015 | - | -$6.67 M(-52.0%) | -$61.05 M(-18.9%) |
| June 2015 | - | -$13.91 M(-23.5%) | -$75.32 M(-13.2%) |
| Mar 2015 | - | -$18.19 M(-18.3%) | -$86.80 M(-4.5%) |
| Dec 2014 | -$90.91 M(+2.1%) | -$22.27 M(+6.4%) | -$90.91 M(+6.3%) |
| Sept 2014 | - | -$20.94 M(-17.5%) | -$85.50 M(-3.3%) |
| June 2014 | - | -$25.39 M(+13.8%) | -$88.38 M(+3.1%) |
| Mar 2014 | - | -$22.30 M(+32.3%) | -$85.76 M(-3.7%) |
| Dec 2013 | -$89.03 M(-9.9%) | -$16.86 M(-29.2%) | -$89.03 M(-8.8%) |
| Sept 2013 | - | -$23.82 M(+4.6%) | -$97.64 M(-1.6%) |
| June 2013 | - | -$22.77 M(-11.0%) | -$99.27 M(-1.9%) |
| Mar 2013 | - | -$25.57 M(+0.4%) | -$101.24 M(+2.4%) |
| Dec 2012 | -$98.84 M | -$25.47 M(+0.1%) | -$98.84 M(-0.3%) |
| Sept 2012 | - | -$25.46 M(+2.9%) | -$99.16 M(+8.2%) |
| June 2012 | - | -$24.74 M(+6.7%) | -$91.63 M(+3.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2012 | - | -$23.17 M(-10.1%) | -$88.37 M(+2.8%) |
| Dec 2011 | -$85.97 M(-326.9%) | -$25.79 M(+43.8%) | -$85.97 M(+11.0%) |
| Sept 2011 | - | -$17.93 M(-16.5%) | -$77.42 M(+754.5%) |
| June 2011 | - | -$21.47 M(+3.3%) | -$9.06 M(-123.0%) |
| Mar 2011 | - | -$20.78 M(+20.5%) | $39.44 M(+4.1%) |
| Dec 2010 | $37.89 M(-134.0%) | -$17.24 M(-134.2%) | $37.89 M(+26.1%) |
| Sept 2010 | - | $50.43 M(+86.6%) | $30.04 M(-163.8%) |
| June 2010 | - | $27.03 M(-221.0%) | -$47.05 M(-54.7%) |
| Mar 2010 | - | -$22.33 M(-11.0%) | -$103.96 M(-6.8%) |
| Dec 2009 | -$111.55 M(-15.7%) | -$25.09 M(-5.8%) | -$111.55 M(-6.9%) |
| Sept 2009 | - | -$26.65 M(-10.8%) | -$119.82 M(-8.4%) |
| June 2009 | - | -$29.88 M(-0.1%) | -$130.86 M(-3.1%) |
| Mar 2009 | - | -$29.92 M(-10.3%) | -$135.01 M(+2.0%) |
| Dec 2008 | -$132.35 M(+78.2%) | -$33.36 M(-11.5%) | -$132.35 M(+12.2%) |
| Sept 2008 | - | -$37.69 M(+10.8%) | -$117.98 M(+18.9%) |
| June 2008 | - | -$34.03 M(+24.8%) | -$99.24 M(+17.5%) |
| Mar 2008 | - | -$27.26 M(+43.5%) | -$84.45 M(+13.7%) |
| Dec 2007 | -$74.27 M(+97.3%) | -$19.00 M(+0.3%) | -$74.27 M(+5.0%) |
| Sept 2007 | - | -$18.94 M(-1.6%) | -$70.73 M(+12.0%) |
| June 2007 | - | -$19.25 M(+12.7%) | -$63.16 M(+36.6%) |
| Mar 2007 | - | -$17.08 M(+10.5%) | -$46.25 M(+22.9%) |
| Dec 2006 | -$37.64 M(-16.8%) | -$15.46 M(+35.8%) | -$37.64 M(+21.1%) |
| Sept 2006 | - | -$11.38 M(+388.5%) | -$31.07 M(-4.7%) |
| June 2006 | - | -$2.33 M(-72.5%) | -$32.60 M(-23.4%) |
| Mar 2006 | - | -$8.47 M(-4.8%) | -$42.56 M(-6.0%) |
| Dec 2005 | -$45.26 M(-19.6%) | -$8.89 M(-31.1%) | -$45.26 M(-11.4%) |
| Sept 2005 | - | -$12.91 M(+5.0%) | -$51.09 M(-5.9%) |
| June 2005 | - | -$12.29 M(+10.1%) | -$54.32 M(-0.1%) |
| Mar 2005 | - | -$11.16 M(-24.2%) | -$54.37 M(-3.4%) |
| Dec 2004 | -$56.26 M(+36.6%) | -$14.73 M(-8.7%) | -$56.26 M(+5.4%) |
| Sept 2004 | - | -$16.14 M(+30.7%) | -$53.39 M(+10.5%) |
| June 2004 | - | -$12.34 M(-5.4%) | -$48.32 M(+4.0%) |
| Mar 2004 | - | -$13.05 M(+10.0%) | -$46.45 M(+12.7%) |
| Dec 2003 | -$41.20 M(+11.3%) | -$11.86 M(+7.2%) | -$41.20 M(+10.1%) |
| Sept 2003 | - | -$11.07 M(+5.8%) | -$37.41 M(+2.5%) |
| June 2003 | - | -$10.47 M(+34.2%) | -$36.48 M(+0.1%) |
| Mar 2003 | - | -$7.80 M(-3.3%) | -$36.46 M(-1.5%) |
| Dec 2002 | -$37.03 M(+55.6%) | -$8.07 M(-20.4%) | -$37.03 M(+5.6%) |
| Sept 2002 | - | -$10.14 M(-2.9%) | -$35.07 M(+12.6%) |
| June 2002 | - | -$10.45 M(+24.8%) | -$31.15 M(+11.2%) |
| Mar 2002 | - | -$8.37 M(+37.0%) | -$28.02 M(+17.7%) |
| Dec 2001 | -$23.80 M(-6.1%) | -$6.11 M(-1.7%) | -$23.80 M(+1.5%) |
| Sept 2001 | - | -$6.22 M(-15.0%) | -$23.46 M(-1.3%) |
| June 2001 | - | -$7.32 M(+75.8%) | -$23.77 M(+3.4%) |
| Mar 2001 | - | -$4.16 M(-27.9%) | -$22.99 M(-9.3%) |
| Dec 2000 | -$25.36 M(+105.1%) | -$5.77 M(-11.7%) | -$25.36 M(+29.4%) |
| Sept 2000 | - | -$6.53 M(0.0%) | -$19.59 M(+50.0%) |
| June 2000 | - | -$6.53 M(0.0%) | -$13.06 M(+100.0%) |
| Mar 2000 | - | -$6.53 M | -$6.53 M |
| Dec 1999 | -$12.37 M | - | - |
FAQ
- What is Rigel Pharmaceuticals annual net profit?
- What is the all time high annual net income for Rigel Pharmaceuticals?
- What is Rigel Pharmaceuticals annual net income year-on-year change?
- What is Rigel Pharmaceuticals quarterly net profit?
- What is the all time high quarterly net income for Rigel Pharmaceuticals?
- What is Rigel Pharmaceuticals quarterly net income year-on-year change?
- What is Rigel Pharmaceuticals TTM net profit?
- What is the all time high TTM net income for Rigel Pharmaceuticals?
- What is Rigel Pharmaceuticals TTM net income year-on-year change?
What is Rigel Pharmaceuticals annual net profit?
The current annual net income of RIGL is -$25.09 M
What is the all time high annual net income for Rigel Pharmaceuticals?
Rigel Pharmaceuticals all-time high annual net profit is $37.89 M
What is Rigel Pharmaceuticals annual net income year-on-year change?
Over the past year, RIGL annual net profit has changed by +$33.48 M (+57.16%)
What is Rigel Pharmaceuticals quarterly net profit?
The current quarterly net income of RIGL is $12.42 M
What is the all time high quarterly net income for Rigel Pharmaceuticals?
Rigel Pharmaceuticals all-time high quarterly net profit is $50.43 M
What is Rigel Pharmaceuticals quarterly net income year-on-year change?
Over the past year, RIGL quarterly net profit has changed by +$18.11 M (+318.22%)
What is Rigel Pharmaceuticals TTM net profit?
The current TTM net income of RIGL is $3.88 M
What is the all time high TTM net income for Rigel Pharmaceuticals?
Rigel Pharmaceuticals all-time high TTM net profit is $39.44 M
What is Rigel Pharmaceuticals TTM net income year-on-year change?
Over the past year, RIGL TTM net profit has changed by +$28.31 M (+115.89%)